Each of the 20 placebo patients was offered the fetal cells 13 months after the original surgery; so far, 14 have gone back for a second operation.

A large proportion of placebo patients took statins during the trial, which weakened the effect.

Serious adverse events were reported in 20% of sunitinib patients and 5% of placebo patients.

Midway through the study, side effects were reported by three placebo patients.

By the end of the study, five placebo patients reported side effects, such as respiratory infection, pain, runny stools, and rash.

The placebo patients will get dummy anti-rejection pills.

After three years, the Azmacort patients had lost significantly more bone mineral density in the spine than the placebo patients.

At least 50% pain relief was achieved in 40-45% of the duloxetine patients vs. 20-22% of placebo patients.

The pain almost completely disappeared, decreasing by more than 90%, in 9-14% of duloxetine patients vs. 2-4% of placebo patients.

Approximately 2.0% of placebo patients enrolled in controlled trials experienced a serious bleeding event over the 28-day period.